triazoles has been researched along with cevipabulin in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (50.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Ayral-Kaloustian, S; Beyer, C; Hernandez, R; Nguyen, T; Zhang, N | 1 |
Ayral-Kaloustian, S; Beyer, CF; Discafani, C; Gibbons, JJ; Hernandez, R; Lucas, J; Nguyen, T; Vitale, D; Zhang, N | 1 |
Ayral-Kaloustian, S; Beyer, CF; Gibbons, JJ; Hernandez, R; Nguyen, T; Vitale, D; Zhang, N | 1 |
Ayral-Kaloustian, S; Beyer, C; Zhang, N | 1 |
Arnold, SM; Bukowski, RM; Cooper, W; Gauthier, E; Lockhart, AC; Rothenberg, ML; Wang, KK; Wang-Gillam, A | 1 |
Ballatore, C; Brunden, KR; Cornec, AS; Crowe, A; James, M; Kovalevich, J; Lee, VM; Smith, AB; Trojanowski, JQ; Yao, Y | 1 |
Ishihara, T; Kakugo, A; Konagaya, A; Nasrin, SR; Rashedul Kabir, AM; Sada, K | 1 |
Alle, T; Ballatore, C; Brunden, KR; Lee, VM; Maimaiti, S; Nzou, G; Trojanowski, JQ; Tsering, W; Yao, Y | 1 |
1 review(s) available for triazoles and cevipabulin
Article | Year |
---|---|
Cevipabulin (TTI-237): preclinical and clinical results for a novel antimicrotubule agent.
Topics: Animals; Antimitotic Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Drug Evaluation, Preclinical; Humans; Hydrocarbons, Halogenated; Mice; Microtubules; Neoplasms; Rats; Triazoles | 2009 |
1 trial(s) available for triazoles and cevipabulin
Article | Year |
---|---|
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Half-Life; Humans; Hydrocarbons, Halogenated; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome; Triazoles; Tubulin Modulators | 2012 |
6 other study(ies) available for triazoles and cevipabulin
Article | Year |
---|---|
2-cyanoaminopyrimidines as a class of antitumor agents that promote tubulin polymerization.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Hydrocarbons, Halogenated; Pyrimidines; Structure-Activity Relationship; Triazoles; Tubulin | 2007 |
TTI-237: a novel microtubule-active compound with in vivo antitumor activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Hydrocarbons, Halogenated; Mice; Mice, Nude; Microtubules; Triazoles; Tubulin; Xenograft Model Antitumor Assays | 2008 |
The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties.
Topics: Antineoplastic Agents; Biopolymers; Cold Temperature; Flow Cytometry; Guanosine Triphosphate; HeLa Cells; Humans; Hydrocarbons, Halogenated; Microtubules; Paclitaxel; Radioligand Assay; Triazoles; Tubulin; Vincristine | 2009 |
Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
Topics: Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier; Cell Division; Dose-Response Relationship, Drug; Female; Hydrocarbons, Halogenated; Male; Mice; Microtubules; Neurons; Proteasome Endopeptidase Complex; Pyrimidines; tau Proteins; Tauopathies; Triazoles; Tubulin | 2016 |
Stabilization of microtubules by cevipabulin.
Topics: Animals; Hydrocarbons, Halogenated; Microscopy, Fluorescence; Microtubules; Molecular Docking Simulation; Molecular Structure; Nanotechnology; Paclitaxel; Protein Stability; Swine; Time-Lapse Imaging; Triazoles; Tubulin | 2019 |
Correction of microtubule defects within Aβ plaque-associated dystrophic axons results in lowered Aβ release and plaque deposition.
Topics: Amyloid beta-Peptides; Animals; Axons; Brain; Disease Models, Animal; Female; Humans; Hydrocarbons, Halogenated; Male; Mice; Mice, Transgenic; Microtubules; Plaque, Amyloid; Triazoles | 2020 |